2025 Drug Trend Report
The 2025 Navitus Drug Trend Report, marks our 10th year of delivering transparent, data-driven insight to help plans, plan sponsors and consultants navigate an increasingly complex prescription drug landscape.
Overall drug trend
In 2025, Navitus clients experienced an overall drug trend increase of 8.4%, driven primarily by rising utilization, specialty medications and continued pharmaceutical innovation. Specialty drug trend rose 11.1%. Non-specialty trend increased 5.6%.
Market pressures
Despite these changes, 32% of Navitus clients paid less than in 2024, and 44% held spending increases to 5% or less, demonstrating how disciplined, evidence-based management and lowest-net-cost strategies can meaningfully moderate cost growth.
Market pressures
Despite these pressures, 32% of Navitus clients paid less than in 2024, and 44% held spending increases to 5% or less—demonstrating how disciplined, evidence-based management and lowest-net-cost strategies can meaningfully moderate cost growth.
The report
Our report examines both 2025 performance and long-term trends, highlighting how utilization, pricing and innovation continue to evolve. Throughout our report, insights from Navitus experts provide guidance for managing specialty risk, navigating utilization growth and leveraging biosimilars and generics.
At Navitus, transparency isn’t a promise — it’s our business model.
For 23 years, we’ve delivered insight that supports smarter decisions and better outcomes. Our goal remains simple: Give clients the clarity they need to take confident, informed action.
For questions and inquiries,
please email [email protected]
For questions and inquiries,
please email [email protected]